These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 14563259)

  • 1. [Chronic C virus infection management].
    García González N; Prieto Valtueña J
    Rev Clin Esp; 2003 Sep; 203(9):443-4. PubMed ID: 14563259
    [No Abstract]   [Full Text] [Related]  

  • 2. Soluble interleukin 2 receptor plasma levels in non-responders with chronic hepatitis C treated with pegylated interferon-alpha 2b and ribavirin.
    Henke H; Schmiegel W; Brechmann T; Voigt E; Griga T
    J Clin Gastroenterol; 2004 Mar; 38(3):301-3. PubMed ID: 15128086
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
    Kim KA
    Korean J Gastroenterol; 2012 Nov; 60(5):273-4. PubMed ID: 23311002
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum lipid profile and chronic hepatitis C virus.
    Purnak T; Efe C; Beyazit Y; Ozaslan E
    Hepatology; 2011 Feb; 53(2):716-7. PubMed ID: 20890943
    [No Abstract]   [Full Text] [Related]  

  • 5. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
    Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
    J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
    [No Abstract]   [Full Text] [Related]  

  • 6. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 7. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Aguilar Reina J
    Rev Esp Enferm Dig; 2009 Oct; 101(10):665-70. PubMed ID: 19899934
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antiviral treatment in liver cirrhosis due to hepatitis C virus].
    Martínez-Bauer E; Forns X
    Gastroenterol Hepatol; 2003 May; 26(5):303-6. PubMed ID: 12732104
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 10. [Chronic hepatitis C: initial treatment in patients without previous treatment].
    Diago M
    Gastroenterol Hepatol; 2002 May; 25(5):347-55. PubMed ID: 11985813
    [No Abstract]   [Full Text] [Related]  

  • 11. Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients.
    Zeuzem S
    J Hepatol; 2008 Aug; 49(2):157-9. PubMed ID: 18554745
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C: CIFN for re-treatment of PEG-IFN plus RBV nonresponders?
    Trepo C; Pradat P
    Nat Rev Gastroenterol Hepatol; 2009 Oct; 6(10):570-1. PubMed ID: 19789573
    [No Abstract]   [Full Text] [Related]  

  • 13. Boceprevir for chronic HCV genotype 1 infection.
    Hsu CS; Kao JH
    N Engl J Med; 2011 Jul; 365(2):176-7; author reply 177-8. PubMed ID: 21751913
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon and ribavirin for hepatitis C.
    Duggan AE; Duggan JM
    N Engl J Med; 2007 Mar; 356(12):1269; author reply 1271. PubMed ID: 17377169
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic hepatitis C virus infection in 2013--quo vadis?
    Prelipcean CC; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2013; 117(1):7-10. PubMed ID: 24505885
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
    Chung WJ
    Clin Mol Hepatol; 2012 Sep; 18(3):268-71. PubMed ID: 23091806
    [No Abstract]   [Full Text] [Related]  

  • 17. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.
    Keeffe EB
    Semin Liver Dis; 2003; 23 Suppl 1():1-2. PubMed ID: 12934161
    [No Abstract]   [Full Text] [Related]  

  • 18. The treatment of viral hepatitis, present and future.
    Rodés J
    J Hepatobiliary Pancreat Surg; 2003; 10(2):163-7. PubMed ID: 14505150
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in treatment of chronic hepatitis C: 'pegylated' interferons.
    Sharieff KA; Duncan D; Younossi Z
    Cleve Clin J Med; 2002 Feb; 69(2):155-9. PubMed ID: 11990646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Taylor LE; Rich JD; Tashima KT
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15564553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.